Fraxetin Pharmaceutical Composition for Endometriosis Recurrence Control

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current treatments for endometriosis, such as surgery and hormone therapy, have high recurrence rates and significant side effects, limiting their effectiveness in managing the condition and improving the quality of life for patients.

Innovation Solution

A pharmaceutical composition containing fraxetin, isolated from Fraxinus rhynchophylla, which inhibits cell proliferation and migration in endometrial cells, induces cell cycle arrest, promotes apoptosis, and increases mitochondrial membrane depolarization and calcium ion accumulation, offering a potential therapeutic or adjuvant treatment for endometriosis.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If surgery or hormone therapy is used to treat endometriosis, then symptom relief is achieved, but recurrence rate increases and side effects occur

Engineering Contradiction:

Improvetreatment effectivenessVSAvoidside effects and recurrence

Core Design Contradiction:

ReliabilityVSObject-generated harmful factors

Solution Approach 1:

The patent changes the chemical parameter from synthetic hormones to natural phytochemicals (fraxetin), altering the molecular structure and mechanism of action to achieve therapeutic effects with reduced side effects. Fraxetin modifies cell proliferation and apoptosis pathways differently than conventional hormones, thereby reducing harmful effects while maintaining treatment effectiveness.

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

The patent employs a natural, biodegradable phytochemical compound that acts locally on endometrial tissue without requiring long-term systemic hormone suppression. This approach replaces persistent synthetic hormones with a shorter-acting natural compound that achieves therapeutic goals with minimal cumulative side effects.

Inventive Principle:

Principle #27Cheap short-living objects (Disposable)

2Object-affected harmful factors

If current hormone therapy is administered, then pelvic pain and dysmenorrhea are relieved, but bone density loss and amenorrhea occur

Engineering Contradiction:

Improvesymptom severityVSAvoidbone density loss and amenorrhea

Core Design Contradiction:

Object-affected harmful factorsVSObject-generated harmful factors

Solution Approach 1:

Fraxetin acts as a natural intermediary compound that mediates between the need for hormone suppression and the avoidance of side effects. It achieves pain relief through anti-inflammatory and anti-proliferative mechanisms without completely suppressing ovarian function, thereby preserving bone density and preventing amenorrhea while still managing endometriosis symptoms.

Inventive Principle:

Principle #24Intermediary (Mediator)

3Ease of operation

If surgery is performed to remove endometriosis tissue, then immediate symptom relief is achieved, but recurrence rate becomes high

Engineering Contradiction:

Improvesymptom relief speedVSAvoiddisease recurrence

Core Design Contradiction:

Ease of operationVSReliability

Solution Approach 1:

The patent employs fraxetin as a preliminary or adjuvant treatment that prevents endometrial cell proliferation and promotes apoptosis before and after surgical intervention. This preliminary action reduces the burden of residual endometriotic tissue, thereby lowering recurrence rates while maintaining the benefits of surgical symptom relief.

Inventive Principle:

Principle #10Preliminary action

Solution Approach 2:

The patent establishes continuous pharmacological action with fraxetin to suppress endometrial cell growth and promote apoptosis over time. This continuous treatment follows surgical intervention to prevent regrowth of endometriotic tissue, ensuring long-term disease control and reducing recurrence despite the initial surgical removal of visible lesions.

Inventive Principle:

Principle #20Continuity of useful action

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

Fraxetin effectively manages endometriosis with fewer side effects by inhibiting cell proliferation, migration, and promoting apoptosis, providing significant therapeutic and preventive effects against the condition and its complications.

Implementation Method 1

Fraxetin increases mitochondrial membrane depolarization

Methodology Applied

Scientific EffectMitochondrial membrane depolarization:

Implementation Method 2

Fraxetin increases mitochondrial membrane depolarization and the accumulation of calcium ions within cells and mitochondria

Methodology Applied

Scientific EffectCalcium ion accumulation:

Data Source

PatentUS20250302799A1Pharmaceutical composition containing fraxetin for prevention or treatment of endometriosis

Publication Date: 2025.10.02 RES & BUSINESS FOUND SUNGKYUNKWAN UNIV

AI summary

Disclosed herein is a pharmaceutical composition for preventing or treating endometriosis, comprising fraxetin. When used as a pharmaceutical composition for preventing or treating endometriosis and complications associated therewith, with fraxetin or a pharmaceutically acceptable salt thereof as an active ingredient, the present disclosure offers effective management of endometriosis with fewer side effects compared to surgery and hormone therapy and thus can be advantageously used as a therapeutic agent for endometriosis and complications associated therewith.